0000000000246653

AUTHOR

Javad Ranjbari

0000-0001-7025-1479

showing 3 related works from this author

Aptamers as smart ligands for nano-carriers targeting

2016

The development of enhanced drug delivery systems is one of the most attractive fields of pharmaceutical sciences, as some of the highly effective chemo/biotherapeutics for cancer treatment can not be administrated due to their high toxicities for normal cells or low stability in physiological media. However, drugs that are currently not administrable will become valuable if specific cell-targeted drug carriers can protect the normal cells from adverse effects and also improve drug pharmacokinetics. Aptamers are attractive and promising biomaterials developed with high affinity and specificity against numerous valuable targets. They could act similar to monoclonal antibodies (mAbs), and off…

0301 basic medicineChemistryNano carriersAptamerNanotechnology02 engineering and technology021001 nanoscience & nanotechnologyAnalytical ChemistryCancer treatment03 medical and health sciences030104 developmental biologyTargeted drug deliveryDrug deliveryPharmaceutical sciencesNanocarriers0210 nano-technologyDrug carrierSpectroscopyTrAC Trends in Analytical Chemistry
researchProduct

Nano-delivery system targeting to cancer stem cell cluster of differentiation biomarkers

2017

Cancer stem cells (CSCs) are one of the most important origins of cancer progression and metastasis. CSCs have unique self-renewal properties and diverse cell membrane receptors that induced the resistance to the conventional chemotherapeutic agents. Therefore, the therapeutic removal of CSCs could result in the cancer cure with lack of recurrence and metastasis. In this regard, targeting CSCs in accordance to their specific biomarkers is a talented attitude in cancer therapy. Various CSCs surface biomarkers have been described, which some of them exhibited similarities on different cancer cell types, while the others are cancer specific and have just been reported on one or a few types of …

0301 basic medicineCellular differentiationPharmaceutical ScienceAntineoplastic AgentsBiologyMetastasis03 medical and health sciencesDrug Delivery Systems0302 clinical medicineTherapeutic indexCancer stem cellBiomarkers TumormedicineAnimalsHumansCluster of differentiationCancerCell Differentiationmedicine.disease030104 developmental biology030220 oncology & carcinogenesisCancer cellImmunologyDrug deliveryNeoplastic Stem CellsCancer researchNanoparticlesJournal of Controlled Release
researchProduct

Targeted cancer therapy through antibody fragments-decorated nanomedicines.

2017

Active targeting in cancer nanomedicine, for improved delivery of agents and diagnose, has been reviewed as a successful way for facilitating active uptake of theranostic agents by the tumor cells. The application of a targeting moiety in the targeted carrier complexes can play an important role in differentiating between tumor and healthy tissues. The pharmaceutical carriers, as main part of complexes, can be polymeric nanoparticles, micelles, liposomes, nanogels and carbon nanotubes. The antibodies are among the natural ligands with highest affinity and specificity to target pharmaceutical nanoparticle conjugates. However, the limitations, such as size and long circulating half-lives, hin…

0301 basic medicineCancer therapyPharmaceutical ScienceAntibody fragments03 medical and health sciences0302 clinical medicineDrug Delivery SystemsNeoplasmsAntibodies BispecificmedicineMoietyAnimalsHumansImmunoglobulin FragmentsLiposomebiologyChemistryCancermedicine.diseaseMolecular biology030104 developmental biologyNanomedicine030220 oncology & carcinogenesisbiology.proteinCancer researchNanomedicineNanoparticlesAntibodyConjugateJournal of controlled release : official journal of the Controlled Release Society
researchProduct